Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol-Reference-Cited by-同舟云学术

Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol

Published:2014-10 Issue:10 Volume:3 Page:143
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT: Pharmacometrics & Systems Pharmacology

Author:

Lacroix B D¹²,Karlsson M O¹,Friberg L E¹

Affiliation:

1. Department of Pharmaceutical Biosciences, Pharmacometrics Group; Uppsala University; Uppsala Sweden

2. UCB Pharma; Braine-l'Alleud Belgium

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1038/psp.2014.41/fullpdf

Reference36 articles.

1. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials;Felson;Arthritis Rheum.,1993

2. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis;Felson;Arthritis Rheum.,1995

3. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?;Felson;Arthritis Rheum.,1998

4. ACR 20: clinical or statistical significance?;Pincus;Arthritis Rheum.,1999

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Difficult‐to‐Treat Psoriatic Arthritis: A Conceptual Approach;Arthritis & Rheumatology;2024-01-24

2. Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors;Clinical Pharmacology & Therapeutics;2024-01-16

3. A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohorts;CPT: Pharmacometrics & Systems Pharmacology;2023-10-03

4. Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity;CPT: Pharmacometrics & Systems Pharmacology;2022-12-25

5. Bridging Fixed Dose to Body Weight-based Regimen of Adalimumab in Paediatric Ulcerative Colitis Using a Pharmacometric Modelling Approach: Case Study with the Phase 3 ENVISION I Trial;Journal of Crohn's and Colitis;2022-05-08